How much cash does Turn Therapeutics Inc. Common Stock generate?

Turn Therapeutics Inc. Common Stock (TTRX) generated -$3.5M in operating cash flow over the trailing twelve months.

Where does Turn Therapeutics Inc. Common Stock's cash flow data come from?

Every line is extracted from Turn Therapeutics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Turn Therapeutics Inc. Common Stock TTRX Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Net income	-$970.97K-196%	——	-$1.9M-186%	——	-$328.55K—
Depreciation and amortization	$14.45K+16.3%	$14.16K+14.5%	——	——	$12.42K—
Stock-based compensation	$280.83K+267%	$256.38K+578%	——	——	$76.6K—
Change in accounts payable	-$613.46K-2,854%	$664.3K+1,213%	——	——	-$20.77K—
Change in other assets	$123.74K-56.9%	-$68.28K-131%	——	——	$287.14K—
Net cash from operating activities	-$1.63M-448%	-$1.18M-173%	——	——	-$298.06K—
Purchases of intangible assets	$12.23K—	$31.44K+301%	——	——	——
Net cash from investing activities	-$12.23K—	-$31.44K-301%	——	——	——
Proceeds from issuance of common stock	——	$100K-80.9%	——	——	$998.09K—
Net cash from financing activities	$7.79M+680%	$3.18M+509%	——	——	$998.09K—
Net cash from discontinued operations	614,152,700%+544,149,300%	420,354,500%+451,194,300%	——	——	70,003,400%—
Amortization	$14.45K+16.3%	——	——	——	$12.42K—
Common Stock Issued In Exchange For Services	——	——	——	——	$250K—
Gain From Change In Fair Value Of Forward Contract Liability	——	-$95.11K—	-$95.11K—	-$95.11K—	-$95.11K—
Gain (Loss) on Derivative Instruments, Net, Pretax	$697.56K+8.4%	$643.74K—	$643.74K—	$643.74K—	$643.74K—
Increase (Decrease) in Prepaid Expense and Other Assets	$123.74K-56.9%	-$68.28K-131%	——	——	$287.14K—
Noncash Operating Lease Expense	——	——	——	——	-$620-129%
Payments to Acquire Intangible Assets	$12.23K—	$31.44K+301%	——	——	——
Cash Receipt From Stock Subscription Receivable	$1.07M—	——	——	——	——
Proceeds From Avenue Capital Loan Agreement	$6.72M—	——	——	——	——
Less: Net increase (decrease) in cash classified within assets held for sale	$6.14M+777%	$1.97M+2,655%	——	——	$700.03K+1,008%
Issuance Of Common Stock Under Avenue Capital Agreement	$1.05M—	——	——	——	——
Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1	——	560,337,200%—	——	——	——
Leased assets obtained in exchange for operating lease liabilities	——	——	——	——	——
Settlement Of Forward Contract Liability For Sale Of Shares To GEM Pursuant To Initial Draw Down Notice	——	$95.11K—	$95.11K—	$95.11K—	$95.11K—
Issuance of common stock for the acquisition of Ansys	——	$212.5K—	$212.5K—	$212.5K—	$212.5K—
Write Off Of Deferred Debt Issuance Cost	$477.65K+284%	$124.24K—	$124.24K—	$124.24K—	$124.24K—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Turn Therapeutics Inc. Common Stock generate?: Turn Therapeutics Inc. Common Stock (TTRX) generated -$3.5M in operating cash flow over the trailing twelve months.
Where does Turn Therapeutics Inc. Common Stock's cash flow data come from?: Every line is extracted from Turn Therapeutics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.